Switch theme
Sign up to access all valuation multiples
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a unique click-on function. The company operates under two reportable segments: diabetes care and delivery systems goods and services. Diabetes care and delivery systems goods and services.
2003
2.8K+
LTM Revenue $900M
LTM EBITDA $286M
$6.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ypsomed has a last 12-month revenue (LTM) of $900M and a last 12-month EBITDA of $286M.
In the most recent fiscal year, Ypsomed achieved revenue of $899M and an EBITDA of $229M.
Ypsomed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ypsomed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $900M | XXX | $899M | XXX | XXX | XXX |
| Gross Profit | $900M | XXX | $351M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 39% | XXX | XXX | XXX |
| EBITDA | $286M | XXX | $229M | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $165M | XXX | $136M | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $145M | XXX | $105M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $277M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ypsomed's stock price is CHF 406 (or $488).
Ypsomed has current market cap of CHF 5.5B (or $6.7B), and EV of CHF 5.8B (or $6.9B).
See Ypsomed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.9B | $6.7B | XXX | XXX | XXX | XXX | $10.59 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ypsomed has market cap of $6.7B and EV of $6.9B.
Ypsomed's trades at 8.3x EV/Revenue multiple, and 31.4x EV/EBITDA.
Equity research analysts estimate Ypsomed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ypsomed has a P/E ratio of 45.9x.
See valuation multiples for Ypsomed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.7B | XXX | $6.7B | XXX | XXX | XXX |
| EV (current) | $6.9B | XXX | $6.9B | XXX | XXX | XXX |
| EV/Revenue | 7.7x | XXX | 8.3x | XXX | XXX | XXX |
| EV/EBITDA | 24.2x | XXX | 31.4x | XXX | XXX | XXX |
| EV/EBIT | 42.1x | XXX | 54.3x | XXX | XXX | XXX |
| EV/Gross Profit | 7.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 45.9x | XXX | 65.0x | XXX | XXX | XXX |
| EV/FCF | -45.8x | XXX | -55.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialYpsomed's last 12 month revenue growth is 1%
Ypsomed's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Ypsomed's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ypsomed's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ypsomed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 38% | XXX | 36% | XXX | XXX | XXX |
| Rule of 40 | 28% | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ypsomed acquired XXX companies to date.
Last acquisition by Ypsomed was XXXXXXXX, XXXXX XXXXX XXXXXX . Ypsomed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ypsomed founded? | Ypsomed was founded in 2003. |
| Where is Ypsomed headquartered? | Ypsomed is headquartered in Switzerland. |
| How many employees does Ypsomed have? | As of today, Ypsomed has 2.8K+ employees. |
| Who is the CEO of Ypsomed? | Ypsomed's CEO is Mr. Simon Michel. |
| Is Ypsomed publicy listed? | Yes, Ypsomed is a public company listed on SWX. |
| What is the stock symbol of Ypsomed? | Ypsomed trades under YPSN ticker. |
| When did Ypsomed go public? | Ypsomed went public in 2004. |
| Who are competitors of Ypsomed? | Similar companies to Ypsomed include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Ypsomed? | Ypsomed's current market cap is $6.7B |
| What is the current revenue of Ypsomed? | Ypsomed's last 12 months revenue is $900M. |
| What is the current revenue growth of Ypsomed? | Ypsomed revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Ypsomed? | Current revenue multiple of Ypsomed is 7.7x. |
| Is Ypsomed profitable? | Yes, Ypsomed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ypsomed? | Ypsomed's last 12 months EBITDA is $286M. |
| What is Ypsomed's EBITDA margin? | Ypsomed's last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of Ypsomed? | Current EBITDA multiple of Ypsomed is 24.2x. |
| What is the current FCF of Ypsomed? | Ypsomed's last 12 months FCF is -$151M. |
| What is Ypsomed's FCF margin? | Ypsomed's last 12 months FCF margin is -17%. |
| What is the current EV/FCF multiple of Ypsomed? | Current FCF multiple of Ypsomed is -45.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
